（原标题：中金：维持康方生物(09926)跑赢行业评级 上调目标价至225.00港元） 智通财经APP获悉，中金发布研报称，维持康方生物(09926)2025年和2026年盈利预测不变。维持跑赢行业评级，该行上调AK112临床成功率并将 Summit AK112再授权预期打入估值，根据DCF模型，该行上调目标价87.5%至225.00港币(33.1%上行空间)。公司公布1H25业绩：收入14.12亿元， 同比增长37.75%，业绩符合该行预期。 HARMONi-A最终分析显示OS取得统计学意义 2025年8月，公司宣布AK112联合化疗用于治疗2L EGFRm NSCLC的HARMONi-A临床公布最终数据，取得具有临床意义和统计学显著的OS获 益，公司未来将在学术大会上公布详细数据。该临床结果上一次更新是2024年5月，OS HR为0.80，成熟度为52%，该行认为该结果进一步证明了 AK112在2L EGFRm NSCLC能够为患者带来明显的生存获益。值得注意的是，目前在2L EGFRm NSCLC尚无上市药物取得OS统计学显著性，IO 代表性药物Keytruda、Opdivo、Tecentriq、Ami ...

Core Viewpoint - UBS has added Kangfang Biotech (09926) to its list of major recommended stocks in the Asia-Pacific region, citing that the overseas potential of its main asset, Edafo, is not fully reflected in the stock price [1] Group 1: Company Analysis - UBS believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress will serve as positive catalysts for the stock price [1] - The target price for Kangfang Biotech has been raised from HKD 197.5 to HKD 224.3, with a "Buy" rating assigned [1] - The valuation of Kangfang Biotech is approximately at the median of the biotech stocks covered by UBS, indicating potential for further outperformance [1] Group 2: Sales Forecasts - UBS has increased its peak sales estimate for Edafo from USD 14.6 billion to USD 16.3 billion [1] - The peak sales estimate for another key asset, Kantani, has been raised from USD 2.2 billion to USD 3.4 billion [1]

瑞银将康方生物加入该行的亚太主要推荐股票名单，认为其主要资产依达方的海外潜力并未于股价全面 反映，该行又认为，有关与跨国企业潜在合作的报道及将在2025年世界肺癌大会发布的HARMONi研 究，为正面的股价催化剂。另一项关键资产开坦尼亦正展开全球注册研发。该行指，康方生物估值大致 处于该行覆盖生物科技股的中位数，该股有空间进一步跑赢。该行上调对依达方海外高峰销售预估，由 146亿美元上调至163亿美元，对开坦尼的海外高峰销售预估由22亿美元上调至34亿美元。目标价由 197.5港元上调至224.3港元，评级"买入"。 消息面上，近日，康方生物公布，2025年世界肺癌大会(WCLC)将于9月6日-9日在西班牙巴塞罗那举 行。会议期间，康方生物海外合作伙伴Summit Therapeutics，将重磅发布公司全球首创PD-1/VEGF双特 异性抗体新药依沃西首个国际多中心注册性Ⅲ期临床HARMONi研究的结果，该研究结果作为Late- Breaking Abstract(LBA)被大会选为口头报告，将在全体会议主席专题研讨会(Presidential Symposium)上 重磅发布。 康方生物(09926)涨超 ...

智通财经APP获悉，康方生物(09926)涨超4%，高见173.8港元创上市新高。截至发稿，涨4.17%，报 172.4港元，成交额12.12亿港元。 消息面上，近日，康方生物公布，2025年世界肺癌大会（WCLC）将于9月6日-9日在西班牙巴塞罗那举 行。会议期间，康方生物海外合作伙伴Summit Therapeutics，将重磅发布公司全球首创PD-1/VEGF双特 异性抗体新药依沃西首个国际多中心注册性Ⅲ期临床HARMONi研究的结果，该研究结果作为Late- Breaking Abstract（LBA）被大会选为口头报告，将在全体会议主席专题研讨会（Presidential Symposium）上重磅发布。 瑞银将康方生物加入该行的亚太主要推荐股票名单，认为其主要资产依达方的海外潜力并未于股价全面 反映，该行又认为，有关与跨国企业潜在合作的报道及将在2025年世界肺癌大会发布的HARMONi研 究，为正面的股价催化剂。另一项关键资产开坦尼亦正展开全球注册研发。该行指，康方生物估值大致 处于该行覆盖生物科技股的中位数，该股有空间进一步跑赢。该行上调对依达方海外高峰销售预估，由 146亿美元上调至163亿 ...

Core Viewpoint - UBS has added Kangfang Biopharma to its list of major recommended stocks in the Asia-Pacific region, believing that the overseas potential of its key asset, Edafo, is not fully reflected in its stock price [1] Group 1: Company Potential - UBS highlights that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress serve as positive catalysts for the stock price [1] - The company is also advancing the global registration and research of another key asset, Okanani [1] Group 2: Financial Estimates - UBS has raised its peak sales forecast for Edafo from $14.6 billion to $16.3 billion and for Okanani from $2.2 billion to $3.4 billion [1] - The target price for Kangfang Biopharma has been increased from HKD 197.5 to HKD 224.3, maintaining a "Buy" rating [1]

Group 1 - Nomura predicts that Kangfang Biotech (09926.HK) will turn from loss to profit in the second half of the year, raising the target price to HKD 120.64 [1] - The company’s mid-term revenue is expected to increase by 42% year-on-year to RMB 1.45 billion, which is 3% lower than market expectations [1] - Sales of the drugs Oritavancin and Ibrutinib are anticipated to accelerate, contributing RMB 800 million and RMB 600 million to mid-term revenue respectively [1] Group 2 - Mid-term operating expenses are projected to be RMB 1.3 billion, with an expected overall mid-term loss attributable to shareholders of RMB 8 million, nearing breakeven [1] - In comparison, the company recorded losses of RMB 239 million and RMB 276 million in the first and second halves of the previous year [1] - For the second half of the year, revenue is forecasted to reach RMB 1.9 billion, driven by sales of Oritavancin and Ibrutinib, with a projected net profit of RMB 271 million [1] Group 3 - The company has adjusted its revenue forecast for the year down by 9.6%, based on lowered expectations for sales and collaboration income from Anika [1] - However, the annual net profit forecast has been raised by 97.2%, based on higher gross margin assumptions [1] - The target price for Kangfang Biotech has been increased from HKD 99.66 to HKD 120.64, while maintaining a neutral rating [1]

Market Overview - The Hang Seng Index closed at 21,973 points, down 7 points, with a trading range of only 255 points, indicating a lack of direction in the market[1] - The market turnover was approximately HKD 163.8 billion, the lowest since February 4[1] - Net inflow from the Hong Kong Stock Connect was HKD 2.12 billion[1] Sector Performance - Major banks and some consumer brands showed strong performance, with four major banks rising between 0.7% and 2.8%[1] - Stocks like Mixue Group and Pop Mart surged between 4.1% and 12.0%, reaching new highs since their listings[1] - Yao Cai Securities saw a significant increase of 81.9% to HKD 5.55, following Ant Group's acquisition[1] Economic Indicators - The upcoming release of China's PMI data and the U.S. GDP for Q1 is expected to increase market volatility[1] - New home sales in 30 major cities fell by 23.3% year-on-year, indicating a continued decline in the real estate market[3] Valuation and Strategy - The current PE ratio of the Hang Seng Index is approximately 9.7 times, suggesting limited downside but requiring effective internal policies for upward movement[2] - Key focus areas for investment include AI infrastructure, consumer demand, and high-dividend state-owned enterprises[2] Coal Market Insights - Yancoal Australia reported a 12.8% year-on-year decline in average coal prices to AUD 157 per ton, influenced by strong market supply[7] - The company’s coal production increased by 8.0% to 9.5 million tons, but sales only rose by 1.2% due to inventory rebuilding[6] Risk Factors - Potential risks include production delays, fluctuations in electricity and steel market demand, and geopolitical uncertainties[11]

Market Overview - The Hong Kong stock market continued its rebound, with the Hang Seng Index rising 2.7% to 21,980 points last week, although it did not stabilize above the 22,000-point mark. The average daily trading volume increased to HKD 238.9 billion, indicating a recovery in capital activity [1] - The Hang Seng Tech Index only increased by 2.0% and failed to break the psychological barrier of 5,000 points, reflecting insufficient recovery momentum in the technology sector [1] - The healthcare and information technology sectors saw significant gains of 8.4% and 6.0%, respectively, while essential consumer goods and telecommunications sectors declined, indicating a rebalancing of funds between policy expectations and risk aversion [1] Economic Policy Insights - The April Politburo meeting maintained policy consistency, emphasizing that "early policy implementation leads to early effects," including accelerated issuance of special bonds and the implementation of long-term special government bonds [2] - The market outlook will depend on two key variables: progress in US-China tariff negotiations and the pace of domestic special bond issuance along with adjustments in real estate policies [2] Industry Dynamics - The Hang Seng Healthcare Index surged 8.9%, significantly outperforming the Hang Seng Index, driven by innovative pharmaceutical companies such as Kangfang (9926 HK), Xinda (1801 HK), and Rongchang (9995 HK) [3] - Kangfang Biotech's (9926 HK) drug, Idataf, received approval for a broader indication in treating non-small cell lung cancer, which is expected to positively impact sales [3] - Rongchang Biotech (9995 HK) reported a good operational performance in Q1, with expectations of a reduction in sales expense ratio by 2025 and a decrease in net losses for shareholders [3] Strategic Recommendations - The report suggests focusing on defensive sectors and policy catalysts, including high-dividend assets from state-owned enterprises, infrastructure-related sectors, and essential consumer goods benefiting from policy stimuli [12] - Monthly stock recommendations include Alibaba-W (9988 HK), China Resources Beverage (2460 HK), and others, indicating a focus on companies with stable earnings and growth potential [12]

智通财经APP获悉，4月23日港股市场，北水成交净卖出181.07亿港元，其中港股通(沪)成交净卖出94.39 亿港元，港股通(深)成交净卖出86.69亿港元。 北水净买入最多的个股是美团-W(03690)、康方生物(09926)、赤峰黄金(06693)。北水净卖出最多的个股 是盈富基金(02800)、恒生中国企业(02828)、中国移动(00941)。 美团-W(03690)获净买入5.57亿港元。消息面上，交银国际发布研报称，行业新进入者或带来短期补贴 波动，但基于美团的规模优势以及领先的商家服务、外卖配送能力，同时考虑新会员体系有望提升用户 粘性及跨场景转化，该行认为行业格局将持续稳定，美团现价对应2025年15倍市盈率，对应17%的利润 增速，下行空间有限。 港股通(深)活跃成交股 | 股票名称 | 买人额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 小米集团-W | 33.87 乙 | 39.14 Z | 73.01亿 | | HK 01810 | | | -5.27 乙 | | 阿里巴巴-W | 23.45亿 | 24.51 乙 ...